Nav: Home

Dr. Dean Bok awarded prestigious Helen Keller Prize for Vision Research

May 03, 2016

SEATTLE, WA, May 3, 2016 - Noted vision researcher Dr. Dean Bok of UCLA will today receive the prestigious 2016 Helen Keller Prize for Vision Research. Keller Johnson-Thompson, a member of the Helen Keller family, will present the prize this evening at a Seattle ceremony coinciding with the annual meeting of the Association for Research in Vision and Ophthalmology.

Dr. Bok is being honored for more than four decades of discoveries in the field of retinal cell biology. He has greatly advanced the scientific study of molecular complexes in the retinal pigment epithelium, or RPE. The RPE permits eyes to function by clearing, on a daily basis, the visual pathway of dead and damaged cells. Dr. Bok has significantly improved the understanding of macular degeneration, which damages vision in as many as 11 million people in the U.S.

"It is a profound honor to be named a Helen Keller Laureate. Blind and deaf from the age of 19 months, Helen Keller represents the ultimate in faith, insight, compassion, tolerance, eloquence and persistence," said Dr. Bok. "I am truly blessed to receive an award that carries her name."

"Helen Keller died in 1968, the same year Dr. Dean Bok received his doctorate degree, and she knew the pace of vision research was accelerating. As much as anyone in subsequent decades, he embodies the progress she foresaw," noted Robert Morris, MD, president and co-founder of the Helen Keller Foundation for Research and Education.

"Because of Dr. Bok we know much more about the eye and retinal disorders," said Stacy Pagos Haller, BrightFocus Foundation president and CEO. "As an organization committed to ending macular degeneration, BrightFocus is proud to honor Dr. Bok as the 2016 Laureate."
-end-
About Dr. Dean Bok

Dean Bok, PhD, is Distinguished Research Professor of Ophthalmology and Neurobiology at the David Geffen School of Medicine at UCLA. He also is a member of the Brain Research Institute of UCLA, and a member and Dolly Green Chair of Ophthalmology at the Jules Stein Eye Institute of UCLA.

About the Helen Keller Prize

The prize was established in 1994 by the Helen Keller Foundation for Research and Education, which was founded in 1988 by Helen Keller's family and scientists dedicated to fighting blindness. The presenting sponsor of the prize, BrightFocus Foundation, is a nonprofit organization supporting research and public awareness to help conquer the brain and eye diseases of Alzheimer's, macular degeneration, and glaucoma.

BrightFocus Foundation

Related Macular Degeneration Articles:

Dietary and lifestyle recommendations for patients at risk of macular degeneration
Age-related macular degeneration (AMD) is a major cause of severe visual impairment in older populations and is characterized by progressive destruction of the retinal pigment epithelial cells and photoreceptors due to low-grade inflammation, ischemia and oxidative stress.
Penn team characterizes the underlying cause of a form of macular degeneration
Using an animal model of Best disease in combination with biochemical and optical assays, a team of researchers at the University of Pennsylvania has pinpointed a number of abnormalities that give rise to the impairments seen in the blinding disease.
Communication from doctors could reduce anxiety for macular degeneration patients
Highly effective current treatments for vision loss need to be allied with careful counselling to ensure patients maintain good psychological health as well as good vision, new research recommends.
Assessing the impact of stress in age-related macular degeneration
Age-related macular degeneration (AMD), the leading cause of vision loss among older adults in the United States, is often associated with psychological stress.
Genetic mutations that lead to macular degeneration blindness mapped by new research
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Clinical trial tests cord tissue to treat macular degeneration
UIC is part of a national phase 2 clinical trial to evaluate the safety and tolerability of using cells derived from multipotent umbilical cord cells to treat age-related macular degeneration, the most common cause of vision loss in people over 55.
Macular degeneration insight identifies promising drugs to prevent vision loss
In a study published this week in the Proceedings of the National Academy of Sciences, a University of Wisconsin-Madison research team pinpoints how immune abnormalities beneath the retina result in macular degeneration, a common condition that often causes blindness.
BrightFocus Foundation honors 5 researchers on macular degeneration and glaucoma
BrightFocus Foundation today recognized five scientists in the fields of macular degeneration and glaucoma research, awarding them grants named in honor of leaders in vision research and advocacy.
Age-related macular degeneration before and after the era of anti-VEGF drugs
In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye.
Discovery identifies new RX target for age-rleated macular degeneration & Alzheimer's
For the first time, researchers at LSU Health New Orleans have shown that a protein critical to the body's ability to remove waste products from the brain and retina is diminished in age-related macular degeneration, after first making the discovery in an Alzheimer's disease brain.

Related Macular Degeneration Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...